希腊转移性割抵抗性前列腺癌患者的真实世界治疗模式:前景研究
M Liontos1, E Bournakis2, A Bournakis2
1Department of Clinical Therapeutics, Alexandra Hospital National and Kapodistrian University of Athens, Athens, Greece.
Clinical genitourinary cancer
|August 27, 2024
概括
现实数据显示,大多数转移性割抵抗性前列腺癌 (mCRPC) 患者开始使用新型荷尔蒙药物 (NHAs). 测序到后来的线路通常涉及化疗,表明需要在mCRPC管理中优化治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 有限的现实世界数据存在,用于管理转移性割耐性前列腺癌 (mCRPC) 的新疗法.
- 了解治疗模式对于优化患者护理至关重要.
研究的目的:
- 分析在希腊开始一线 (1L) 治疗的mCRPC患者的现实管理策略.
- 描述从1L到二线 (2L) 和三线 (3L) 治疗的治疗序列.
主要方法:
- 一项回顾性,非干预性研究 (PROSPECT) 审查了149名mCRPC患者的病历.
- 从7个主要的希腊抗癌医院诊所收集了数据.
- 使用了描述性分析和卡普兰-梅尔方法.
主要成果:
- 大多数患者 (78.5%) 接受1L的新型激素药物 (NHAs),主要是恩扎胺和阿比拉.
- 在2L中,化疗 (docetaxel) 是最常见的 (72.1%).
- 从1L到2L的治疗顺序主要涉及NHA到化疗 (55.9%). 平均治疗持续时间为9.8个月 (1L),4.4个月 (2L) 和3.7个月 (3L).
结论:
- 一线NHA的使用符合mCRPC的指导方针.
- 用1L的NHAs治疗时间更长表明2L和3L治疗优化改善的潜力.
- 需要进一步的研究来完善mCRPC的顺序治疗建议.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...